JP2024541533A5 - - Google Patents
Info
- Publication number
- JP2024541533A5 JP2024541533A5 JP2024531423A JP2024531423A JP2024541533A5 JP 2024541533 A5 JP2024541533 A5 JP 2024541533A5 JP 2024531423 A JP2024531423 A JP 2024531423A JP 2024531423 A JP2024531423 A JP 2024531423A JP 2024541533 A5 JP2024541533 A5 JP 2024541533A5
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- pyran
- cancer
- tetrahydro
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020132454 | 2020-11-27 | ||
| CN2021081236 | 2021-03-17 | ||
| PCT/CN2021/133429 WO2022111621A1 (en) | 2020-11-27 | 2021-11-26 | Aminoheteroaryl kinase inhibitors |
| CNPCT/CN2021/133429 | 2021-11-26 | ||
| PCT/CN2022/133770 WO2023093769A1 (en) | 2020-11-27 | 2022-11-23 | Aminoheteroaryl kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024541533A JP2024541533A (ja) | 2024-11-08 |
| JP2024541533A5 true JP2024541533A5 (cg-RX-API-DMAC10.html) | 2025-11-28 |
Family
ID=81753779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531615A Active JP7895947B2 (ja) | 2020-11-27 | 2021-11-26 | アミノヘテロアリールキナーゼ阻害剤 |
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531615A Active JP7895947B2 (ja) | 2020-11-27 | 2021-11-26 | アミノヘテロアリールキナーゼ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240166635A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4251613A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7895947B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230127228A (cg-RX-API-DMAC10.html) |
| CN (3) | CN122483000A (cg-RX-API-DMAC10.html) |
| AU (3) | AU2021385745C1 (cg-RX-API-DMAC10.html) |
| CA (2) | CA3202990A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL303237A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024006300A (cg-RX-API-DMAC10.html) |
| WO (2) | WO2022111621A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4251613A4 (en) * | 2020-11-27 | 2024-11-20 | Allorion Therapeutics Inc. | AMINOHETEROARYL KINASE INHIBITORS |
| US20250009745A1 (en) * | 2021-02-05 | 2025-01-09 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Cdk inhibitor |
| CN119343333A (zh) * | 2022-05-27 | 2025-01-21 | 安锐生物医药公司 | 氨基杂芳基激酶抑制剂 |
| WO2025006400A1 (en) * | 2023-06-25 | 2025-01-02 | Allorion Therapeutics Inc | Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| EP4725942A1 (en) * | 2024-10-09 | 2026-04-15 | Sibylla Biotech S.p.A. | Compounds active on cyclin d1 pathway and their use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| MXPA03005696A (es) * | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
| IL159120A0 (en) * | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| HUP0402245A3 (en) * | 2001-11-01 | 2010-03-29 | Janssen Pharmaceutica Nv | Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005526765A (ja) | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 |
| WO2004048343A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| ATE541848T1 (de) * | 2005-05-05 | 2012-02-15 | Ardea Biosciences Inc | Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv |
| AU2007338792B2 (en) * | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| EP2142550A1 (en) * | 2007-04-02 | 2010-01-13 | Palau Pharma, S.A. | Pyrrolopyrimidine derivatives as jak3 inhibitors |
| MX2009011199A (es) | 2007-04-16 | 2010-03-17 | Hutchison Medipharma Entpr Ltd | Derivados de pirimidina. |
| DK2146779T3 (en) * | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| WO2009022171A1 (en) | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| EP2179992A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| TW201024281A (en) * | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| US9145402B2 (en) * | 2011-11-29 | 2015-09-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
| NZ629830A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| CN110386901B (zh) | 2018-04-23 | 2022-11-25 | 上海医药工业研究院 | 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用 |
| US12037323B2 (en) | 2018-05-03 | 2024-07-16 | Bristol-Myers Squibb Company | Uracil derivatives as Mer-AXL inhibitors |
| US11919904B2 (en) * | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| JP2023515629A (ja) * | 2020-02-28 | 2023-04-13 | フォチョン・バイオサイエンシーズ・リミテッド | Cdk2/4/6阻害剤としての化合物 |
| WO2022096473A1 (en) * | 2020-11-04 | 2022-05-12 | Umicore | A positive electrode active material for rechargeable batteries |
| EP4251613A4 (en) * | 2020-11-27 | 2024-11-20 | Allorion Therapeutics Inc. | AMINOHETEROARYL KINASE INHIBITORS |
| US20250009745A1 (en) * | 2021-02-05 | 2025-01-09 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Cdk inhibitor |
-
2021
- 2021-11-26 EP EP21897121.6A patent/EP4251613A4/en active Pending
- 2021-11-26 KR KR1020237021724A patent/KR20230127228A/ko active Pending
- 2021-11-26 US US18/254,573 patent/US20240166635A1/en active Pending
- 2021-11-26 CN CN202610430533.6A patent/CN122483000A/zh active Pending
- 2021-11-26 AU AU2021385745A patent/AU2021385745C1/en active Active
- 2021-11-26 IL IL303237A patent/IL303237A/en unknown
- 2021-11-26 JP JP2023531615A patent/JP7895947B2/ja active Active
- 2021-11-26 CA CA3202990A patent/CA3202990A1/en active Pending
- 2021-11-26 WO PCT/CN2021/133429 patent/WO2022111621A1/en not_active Ceased
- 2021-11-26 CN CN202180079929.6A patent/CN116528869B/zh active Active
-
2022
- 2022-11-23 EP EP22897852.4A patent/EP4436959A4/en active Pending
- 2022-11-23 WO PCT/CN2022/133770 patent/WO2023093769A1/en not_active Ceased
- 2022-11-23 MX MX2024006300A patent/MX2024006300A/es unknown
- 2022-11-23 JP JP2024531423A patent/JP2024541533A/ja active Pending
- 2022-11-23 CN CN202280077473.4A patent/CN118475562A/zh active Pending
- 2022-11-23 CA CA3238970A patent/CA3238970A1/en active Pending
- 2022-11-23 AU AU2022397678A patent/AU2022397678A1/en active Pending
-
2024
- 2024-05-21 US US18/670,469 patent/US20250002480A1/en active Pending
-
2025
- 2025-01-02 AU AU2025200001A patent/AU2025200001A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111201223B (zh) | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 | |
| JP6524221B2 (ja) | Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| JP2022058514A (ja) | メニン-mll相互作用の阻害剤 | |
| CN115947681B (zh) | 整合应激通路的调节剂 | |
| JP5852678B2 (ja) | 抗腫瘍剤の効果増強剤 | |
| JP2024023295A (ja) | Shp2の活性を阻害するための化合物の製造方法 | |
| TWI609012B (zh) | 氨基喹唑啉類衍生物及其鹽和使用方法 | |
| TWI693220B (zh) | 1,3,4-噻二唑化合物及其用於治療癌症之用途 | |
| JP2023533938A5 (cg-RX-API-DMAC10.html) | ||
| CN113993591A (zh) | 新egfr抑制剂 | |
| JP2020090535A (ja) | 癌の処置のためのウリジンのジオキソラン類似体 | |
| TWI448461B (zh) | 4-aniline-6-butenamide-7-alkyl ether quinazoline derivatives, methods and uses thereof | |
| US20160175284A1 (en) | Estrogen receptor modulators and uses thereof | |
| RU2770824C2 (ru) | Противоопухолевый агент | |
| CN111643496A (zh) | 使用mek抑制剂的方法 | |
| JP6549115B2 (ja) | 新規抗癌剤 | |
| TW201936585A (zh) | 5-氟尿嘧啶化合物 | |
| TW202114985A (zh) | Ep拮抗劑 | |
| WO2023093769A1 (en) | Aminoheteroaryl kinase inhibitors | |
| JP4852605B2 (ja) | 放射線治療増強剤 | |
| RU2483064C2 (ru) | Твердые формы ингибитора raf-киназы | |
| JP2024515061A5 (cg-RX-API-DMAC10.html) | ||
| US20250345339A1 (en) | Doses and regimens of her2 inhibitors | |
| JP7733273B2 (ja) | G12d変異kras阻害活性を有する二官能性化合物を含む抗がん剤の組合せ | |
| WO2021025976A1 (en) | Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same |